Friday, 16 October 2026European Markets

LERØY SEAFOOD GP, MOWI, Another 1 Companies Have A High Dividend Yield And Return On Equity In The Consumer Defensive Sector.

Loading stream...

(VIANEWS) - LERØY SEAFOOD GP (LSG.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Consumer Defensive sector.

Financial Asset Price Forward Dividend Yield Return on Equity
LERØY SEAFOOD GP (LSG.OL) kr42.78 5.55% 3.73%
MOWI (MOWI.OL) kr174.65 4.33% 10.75%
HEINEKEN (HEIA.AS) €83.88 2.31% 12.7%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. LERØY SEAFOOD GP (LSG.OL)

5.55% Forward Dividend Yield and 3.73% Return On Equity

Lerøy Seafood Group ASA produces, processes, markets, sells, and distributes seafood products worldwide. It operates in three segments: Wildcatch; Farming; and Value-Added Processing, Sales and Distribution. The company offers smoked and gravad salmon, and trout products; farmed and wild catch whole fishes; fillets and portions; ready-to-eat and ready-to-cook products; fish blocks and cubes; breaded products; pre-fried fish burgers and patties; crustaceans and molluscs; seaweeds; and other products. Lerøy Seafood Group ASA markets its products primarily under the Norway Seafoods, Arctic Supreme, Fjord trout, Aurora Salmon, Fossen, Sea Eagle, Lerøy, and M?r brands to shops, restaurants, canteens, and hotels. The company was founded in 1899 and is headquartered in Bergen, Norway. Lerøy Seafood Group ASA is a subsidiary of Austevoll Seafood ASA.

Earnings Per Share

As for profitability, LERØY SEAFOOD GP has a trailing twelve months EPS of kr1.

PE Ratio

LERØY SEAFOOD GP has a trailing twelve months price to earnings ratio of 42.78. Meaning, the purchaser of the share is investing kr42.78 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 3.73%.

More news about LERØY SEAFOOD GP.

2. MOWI (MOWI.OL)

4.33% Forward Dividend Yield and 10.75% Return On Equity

Mowi ASA, a seafood company, produces and supplies farmed salmon products worldwide. It operates through three segments: Feed, Farming, and Sales and Marketing. The company is involved in the salmon feed production, salmon farming and primary processing, and seafood secondary processing activities. It offers whole gutted fish, including Label Rouge and organic salmon; and white fish and other seafood products, as well as fillets, steaks, cutlets, portions, loins, kebabs, and steak combos. The company also provides value added products, such as breaded, pre-fried, dusted, marinated, grilled, battered, topped, filled with sauce, delicatessen, fresh fish ready meal, and smoked fish products. It offers its products under the Mowi, Mowi Salmon, Donegal Silver, Admiral's, Pieters, Laschinger, Kritsen, Ducktrap River, Harbour Salmon Co., Rebel Fish, Supreme Salmon, Olav's, Northern Harvest, and Mowi Nutrition brand names. The company was formerly known as Marine Harvest ASA and changed its name to Mowi ASA in December 2018. Mowi ASA was founded in 1964 and is headquartered in Bergen, Norway.

Earnings Per Share

As for profitability, MOWI has a trailing twelve months EPS of kr8.51.

PE Ratio

MOWI has a trailing twelve months price to earnings ratio of 20.52. Meaning, the purchaser of the share is investing kr20.52 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.75%.

Volume

Today's last reported volume for MOWI is 582814 which is 18.08% below its average volume of 711479.

More news about MOWI.

3. HEINEKEN (HEIA.AS)

2.31% Forward Dividend Yield and 12.7% Return On Equity

Heineken N.V. brews and sells beer and cider in Europe, Americas, Africa, the Middle East, Eastern Europe, and the Asia Pacific. The company also provides soft drinks and water. It offers its beers under the Heineken, Amstel, Sol, Tiger, Birra Moretti, Pure Piraña, Desperados, Edelweiss, and Lagunitas brands; and cider under the Strongbow Apple Ciders, Orchard Thieves, Cidrerie Stassen, Bulmers, and Old Mout brands, as well as under regional and local brands. The company offers its products to retailers, wholesalers, cafes, bars, pubs, hotels, and restaurants. Heineken N.V. was founded in 1864 and is headquartered in Amsterdam, the Netherlands. Heineken N.V. operates as a subsidiary of Heineken Holding N.V.

Earnings Per Share

As for profitability, HEINEKEN has a trailing twelve months EPS of €4.49.

PE Ratio

HEINEKEN has a trailing twelve months price to earnings ratio of 18.68. Meaning, the purchaser of the share is investing €18.68 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.7%.

Volume

Today's last reported volume for HEINEKEN is 199076 which is 71.1% below its average volume of 689012.

More news about HEINEKEN.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com